Akeso, Inc. (HKEX Code: 9926. HK) is a biopharmaceutical company founded by a team of scientists with rich experience in global drug development and focuses on the unmet clinical needs worldwide in major diseases. The Company has created a unique integrated R&D innovation system with a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) ，ADC technology ，SiRNA，mRNA technology and the cell therapy technology as the core, a GMP-compliant manufacturing system, and a commercialization system with an advanced operation mode.
Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values so as to become a leading global biopharmaceutical enterprise.
We have been identifying strategic partners globally with high value-added potential
to cooperate in partnership, joint venture, or licensing agreement
We focuse on major disease areas such as oncology, autoimmune diseases, inflammation, metabolic diseases and neurodegenerative diseases, with robust R&D capabilities and remarkable innovative achievements
